Literature DB >> 32550246

HLA predictions from the bronchoalveolar lavage fluid samples of five patients at the early stage of the wuhan seafood market COVID-19 outbreak.

René L Warren1, Inanç Birol1.   

Abstract

We are in the midst of a global viral pandemic, one with no cure and a high mortality rate. The Human Leukocyte Antigen (HLA) gene complex plays a critical role in host immunity. We predicted HLA class I and II alleles from the transcriptome sequencing data prepared from the bronchoalveolar lavage fluid samples of five patients at the early stage of the COVID-19 outbreak. We identified the HLA-I allele A*24:02 in four out of five patients, which is higher than the expected frequency (17.2%) in the South Han Chinese population. The difference is statistically significant with a p-value less than 10-4. Our analysis results may help provide future insights on disease susceptibility.

Entities:  

Keywords:  COVID-19; HLA-A*24:02; HLA-DPA1*02:02; HLA-DPB1*05:01; Human Leukocyte Antigen (HLA); RNA-Seq; SARS-Cov-2; bronchoalveolar lavage fluid

Year:  2020        PMID: 32550246      PMCID: PMC7280900     

Source DB:  PubMed          Journal:  ArXiv        ISSN: 2331-8422


Introduction

SARS-CoV-2 infections have reached global pandemic proportions in early 2020, affecting over 2M people worldwide (as of this writing) and showing no signs of easing, except in a few jurisdictions where strict quarantine measures were implemented early on. The resulting coronavirus disease (COVID-19) has a relatively high (~3.4%) mortality rate [1] – a figure that varies widely between jurisdictions due to factors yet to be determined. Currently, no vaccines or effective treatments are available. Most current data analysis efforts are, understandably, focused on the virus itself for the purpose of vaccine development and tracking its evolution for diagnostics and infection monitoring purposes. Curiously, it is estimated that as high as 18–30% or more of the population may be asymptomatic to SARS-CoV-2 infections [2] [3], while other affected individuals exhibit mild to severe to critical symptoms of infection. Thus, gaining insights on host susceptibility to the coronavirus is clearly another important aspect that needs to be worked on and understood. One would expect a link between host immunity genes and susceptibility or resistance to infection. The Human Leukocyte Antigen (HLA) gene complex includes two classes of such genes, which encode the Major Histocompatibility Complex (MHC). Proteins of the MHC present (class I) internally- or (class II) externally-derived antigenic determinants (epitopes) to T cells, which upon recognition of the epitope-complex, will mount an immune response to defend against viral and bacterial infections. HLA genes are therefore cornerstone to acquired immunity in humans. HLA alleles have also been shown to be factors in susceptibility or resistance to certain diseases, and their frequency and composition in human populations vary widely (http://allelefrequencies.net). A previous study found HLA class I genes HLA-B*46:01 and HLA-B*54:01 to be associated with the 2003 severe acute respiratory syndrome (SARS) coronavirus infections in Taiwan [4] – a related disease to the current pandemic. For over a decade, high-throughput transcriptome sequencing (RNA-Seq) has proven a worthy instrument for measuring changes of gene expression in human diseases and beyond [5]. Transcriptome analysis has the potential to reveal key genes that are modulated in response to infections, but also to reveal the HLA composition of affected individuals. A few years ago, our group developed an approach for mining high-throughput next-generation shotgun sequencing data for the purpose of HLA determination [6], which has since been applied in a broader clinical context [7]. Here, we report our initial observations based on transcriptome sequencing libraries prepared from the bronchoalveolar lavage fluid samples of five patients at the early stage of the Wuhan seafood market pneumonia coronavirus outbreak (see Methods). We identified the HLA class I allele A*24:02 and class II haplotype DPA1*02:02-DPB1*05:01 in four out of five individuals. Although HLA-A*24:02 is common in some populations, the prevalence observed (80%) is higher than the allele frequency in the Chinese population (17.2%) — the presumed ethnicity of the patients in the reported study.

Methods

We downloaded MGISEQ-2000RS paired-end (150 bp) RNA-Seq reads from libraries prepared from the bronchoalveolar lavage fluid samples of five patients (https://www.ebi.ac.uk/ena/data/view/PRJNA605983 Accessions: SRX7730880-SRX7730884 denoted in the tables below as Patient 1–5, respectively). We note that these are metagenomics RNA samples, and, although not explicitly noted, we think that they were prepared for the primary purpose of identifying and characterizing the novel coronavirus at the outbreak epicentre. On each dataset, we ran HLAminer [6] in targeted assembly mode with default values (v1.4; contig length ≥200bp, seq. identity ≥99%, score ≥1000), predicting HLA class I (HLA-I) and class II (HLA-II) alleles and report 4-digit (HLA allele/protein) resolution when top-scoring predictions are unambiguous. Otherwise the 2-digit (allele group) resolution is reported.

Results

We predicted and compiled the likely HLA class I (Table 1) and II (Table 2) alleles for five patients at the early stage of the COVID-19 outbreak in Wuhan, China. Although the bronchoalveolar lavage (BAL) fluid samples were initially utilized to identify and characterize the novel coronavirus (similar justification in [8]), BAL metagenomics samples are expected to contain host cells / nucleic acids (DNA/RNA). Because HLA genes are expressed at the surface of all human nucleated cells, RNA-Seq data can be employed to determine HLA profiles from BAL samples.
Table 1:

HLA-I predictions from the bronchoalveolar lavage fluid samples of five patients at the early stage of the Wuhan seafood market pneumonia coronavirus outbreak. Highest-scoring HLAminer predictions are shown for HLA class I genes A, B and C. Common HLA alleles between two or more patients are highlighted in bold face.

Patient 1Patient 2Patient 3Patient 4Patient 5
A*01:01PA*30:01PA*24:02PA*24:02PA*29
A*24:02PA*02:06PA*26:01P-A*24

B*35/B*57B*51:01PB*15:01PB*40:01PB*54:01P
B*48B*13:02PB*51:01PB*13:01PB*07:05P

C*08:72PC*14:02PC*15:02PC*04:03PC*15
C*06:02PC*06:02PC*03:03PC*03:04P-
Table 2:

HLA-II predictions from the bronchoalveolar lavage fluid samples of five patients at the early stage of the Wuhan seafood market pneumonia coronavirus outbreak. Highest-scoring HLAminer predictions are shown for HLA class II genes DPA1, DPB1, DQA1, DQB1, DRA, DRB1, DRB3, DRB4 and DRB5. Missing class II genes or (-) denote the absence of predictions. Common HLA alleles between two or more patients are highlighted in bold face.

Patient 1Patient 2Patient 3Patient 4Patient 5
DPA1*02:02PDPA1*02:01PDPA1*02:02PDPA1*02:02PDPA1*04:01P
-DPA1*02:02P---

DPB1*05:01PDPB1*13:01PDPB1*05:01PDPB1*05:01P-
DPB1*02:02PDPB1*05:01P---

DQA1*01:03PDQA1*01:02PDQA1*03:01PDQA1*01:01P-
DQA1*05DQA1*02:01P-DQA1*05:01P-

DQB1*03:01PDQB1*05:02PDQB1*04:01PDQB1*03:01P-
DQB1*06:01PDQB1*02:01PDQB1*03:02P--

DRA*01:01PDRA*01:01PDRA*01:01P--
-----

DRB1*08:03PDRB1*07:01PDRB1*04:03PDRB1*15:02PDRB1*04
-DRB1*16:02PDRB1*04:05PDRB1*11:01P-

---DRB3*02:02P-
-----

-DRB4*01:01PDRB4*01:01P--
-----

-DRB5*02:02P-DRB5*01:02-
-----
We observe the HLA-A*24:02 allele in four out of five (80%) patients (Table 1). HLA-A*24 is a common group of alleles in Southeastern Asian populations, and the frequency of HLA-A*24:02 allele is high, especially in indigenous Taiwanese populations, reaching as high as 86.3%. However, our understanding is that the five patients are from the Wuhan market area, and the associated A*24:02 frequency in Chinese population is typically 17.2%, a value that is statistically significantly less than our observed frequency of 80% (p< 10−4, 1-sided z-test). Also of note, the HLA class II DPA1*02:02 andDPB1*05:01 haplotype predicted in patients 1 to 4 (80%), genes DQB1*03:01 in patients 1 and 4, and DRB4*01:01 in patients 2 and 3 (Table 2).

Discussion and Conclusions

HLA-A*24 has not been previously reported as a risk factor for SARS infection [9], but there are reports of disease association with HLA-A*24:02, notably with diabetes [10] [11] [12] [13], which is a reported potential risk factor in COVID-19 patients [14]. Both DPA1*02:02 andDPB1*05:01 occur at relative high frequency (44.8% and 31.3%, n=1490) in Han Chinese [15], and associations of those HLA type II alleles with narcolepsy [16] and Graves’ disease [15], both autoimmune disorders, have been reported in that population. Further, a GWAS study found a link between HLA-DPB1*05:01 and chronic hepatitis B in Asians, and it has been suggested that this risk allele may impact one’s ability to clear viral infections [16] [17]. HLA also informs vaccine development. This knowledge would help prioritize SARS-CoV-2 derived epitopes predicted to be stable HLA binders [18] [19]. Future studies into host susceptibility and resistance to SARS-CoV-2 infections are sorely needed as they may help us better manage and mitigate risks of infections. We chose to communicate our early findings in this domain to facilitate rapid development of response strategies.
  16 in total

1.  The HLA class I A locus affects susceptibility to type 1 diabetes.

Authors:  Janelle A Noble; Ana M Valdes; Teodorica L Bugawan; Raymond J Apple; Glenys Thomson; Henry A Erlich
Journal:  Hum Immunol       Date:  2002-08       Impact factor: 2.850

2.  A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.

Authors:  Yoichiro Kamatani; Sukanya Wattanapokayakit; Hidenori Ochi; Takahisa Kawaguchi; Atsushi Takahashi; Naoya Hosono; Michiaki Kubo; Tatsuhiko Tsunoda; Naoyuki Kamatani; Hiromitsu Kumada; Aekkachai Puseenam; Thanyachai Sura; Yataro Daigo; Kazuaki Chayama; Wasun Chantratita; Yusuke Nakamura; Koichi Matsuda
Journal:  Nat Genet       Date:  2009-04-06       Impact factor: 38.330

Review 3.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

4.  Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.

Authors:  Scott D Brown; Rene L Warren; Ewan A Gibb; Spencer D Martin; John J Spinelli; Brad H Nelson; Robert A Holt
Journal:  Genome Res       Date:  2014-04-29       Impact factor: 9.043

5.  Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  Austin Nguyen; Julianne K David; Sean K Maden; Mary A Wood; Benjamin R Weeder; Abhinav Nellore; Reid F Thompson
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

6.  Fine mapping MHC associations in Graves' disease and its clinical subtypes in Han Chinese.

Authors:  Xun Chu; Minjun Yang; Zhen-Ju Song; Yan Dong; Chong Li; Min Shen; Yong-Qiang Zhu; Huai-Dong Song; Sai-Juan Chen; Zhu Chen; Wei Huang
Journal:  J Med Genet       Date:  2018-07-09       Impact factor: 6.318

7.  Derivation of HLA types from shotgun sequence datasets.

Authors:  René L Warren; Gina Choe; Douglas J Freeman; Mauro Castellarin; Sarah Munro; Richard Moore; Robert A Holt
Journal:  Genome Med       Date:  2012-12-10       Impact factor: 11.117

8.  The many estimates of the COVID-19 case fatality rate.

Authors:  Dimple D Rajgor; Meng Har Lee; Sophia Archuleta; Natasha Bagdasarian; Swee Chye Quek
Journal:  Lancet Infect Dis       Date:  2020-03-27       Impact factor: 25.071

9.  Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).

Authors:  Hiroshi Nishiura; Tetsuro Kobayashi; Takeshi Miyama; Ayako Suzuki; Sung-Mok Jung; Katsuma Hayashi; Ryo Kinoshita; Yichi Yang; Baoyin Yuan; Andrei R Akhmetzhanov; Natalie M Linton
Journal:  Int J Infect Dis       Date:  2020-03-14       Impact factor: 3.623

10.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.

Authors:  Wei-Jie Guan; Wen-Hua Liang; Yi Zhao; Heng-Rui Liang; Zi-Sheng Chen; Yi-Min Li; Xiao-Qing Liu; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Chun-Quan Ou; Li Li; Ping-Yan Chen; Ling Sang; Wei Wang; Jian-Fu Li; Cai-Chen Li; Li-Min Ou; Bo Cheng; Shan Xiong; Zheng-Yi Ni; Jie Xiang; Yu Hu; Lei Liu; Hong Shan; Chun-Liang Lei; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Lin-Ling Cheng; Feng Ye; Shi-Yue Li; Jin-Ping Zheng; Nuo-Fu Zhang; Nan-Shan Zhong; Jian-Xing He
Journal:  Eur Respir J       Date:  2020-05-14       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.